Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total ...

Respiratory vaccines specialist Vicebio Ltd. is to be acquired by Sanofi SA in a $1.6 billion deal, of which $1.15 billion ...

Astra, led by boss Pascal Soriot (pictured), said it is accelerating its expansion in US with an investment that will create ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

Sanofi will acquire Vicebio for USD 1.15 bn, gaining RSV/hMPV vaccine candidates plus the Molecular Clamp platform for refrigeration‑stable combination vaccines. Deal expected by Q4 2025, supporting ...

The global Vaccines Market is estimated to be valued at USD 54.50 billion in 2025 and is projected to reach USD 111.3 billion ...

In a move to bolster its drug manufacturing capabilities in the United States, Thermo Fisher has purchased a sterile fill-finish and packaging plant from Sanofi in Ridgefield, New Jersey.

The global travel vaccines market size was US$ 6.1 billion in 2021. The global travel vaccines market is forecast to grow to US$ 12.1 billion by 2030 by registering a compound annual growth rate (CAGR ...